Japan's Ministry Continues Safety Measures On AstraZeneca's Iressa
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare's Pharmaceutical Safety Committee decided August 1 to continue current safety measures and side effects monitoring regarding AstraZeneca's lung cancer drug Iressa (gefitinib). The committee also summarized and confirmed the drug's clinical benefits. Since last February, the committee has conducted trials comparing gefitinib with other AstraZeneca cancer drugs, and the committee concluded that the results need further analyzing. Iressa has been the center of attention since serious side effects were reported in Japan. (Click here for more - Japanese language
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.